Tigecycline-induced acute pancreatitis in a cystic fibrosis patient: A case report and literature review.
OBJECTIVE
The purpose of this case report is to increase awareness of tigecycline-associated pancreatitis, specifically in patients who may be predisposed to develop pancreatitis.


METHODS
A 22-year-old male with cystic fibrosis developed acute bronchitis, with sputum cultures significant for Mycobacterium chelonae. He was started on tigecycline on two separate occasions, in each case developing pancreatitis as evidenced by symptomatology, elevated pancreatic enzymes and, in one case, by CT imaging. On both occasions, symptomatology improved and enzymes normalized after discontinuation of tigecycline.


CONCLUSIONS
Current literature including two recent review pieces is discussed. The unique aspects of the case are highlighted, including the particular risk of drug-associated pancreatitis in those with cystic fibrosis.


CONCLUSIONS
The results of this case, in the context of current literature, suggest that clinicians should be aware of the potential for pancreatitis when using tigecycline. Clinicians should be particularly mindful of this complication in patients with comorbidities that might increase the risk of pancreatitis above that of the general population.
Department of Internal Medicine, PO Box 26901, WP1140, Oklahoma City, OK 73126-0901, USA. Electronic address: michael-hemphill@ouhsc.edu.
Michael T
MT
Hemphill
Department of Internal Medicine, Pulmonary and Critical Care Division, PO Box 26901, WP1310, Oklahoma City, OK 73190, USA. Electronic address: kellie-jones@ouhsc.edu.
Kellie R
KR
Jones
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D001991:Bronchitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D003550:Cystic Fibrosis / Q000150:complications*; D019468:Disease Management; D006801:Humans; D008297:Male; D008911:Minocycline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016926:Mycobacterium chelonae / Q000302:isolation & purification*; D010195:Pancreatitis / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D020379:Risk Adjustment; D000078304:Tigecycline; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline
Cystic fibrosis; Pancreatitis; Tigecycline